NovaBridge Biosciences (NBP) Total Liabilities (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Total Liabilities for 8 consecutive years, with $29.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Liabilities rose 156.78% year-over-year to $29.6 million; the TTM figure through Dec 2025 stood at $29.6 million (up 156.78% YoY), while the FY2025 annual figure was $29.6 million, up 156.78% from the prior year.
• Total Liabilities improved to $29.6 million in Q4 2025 per NBP's latest filing, from $18.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $163.6 million in Q4 2022 and bottomed at $10.0 million in Q2 2025.
• Historically, Total Liabilities has averaged $74.0 million across 5 years, with a median of $29.6 million in 2025.
• Annual changes were most pronounced in 2024 — Total Liabilities slumped 90.73% — and 2025, when it surged 156.78%.
• NovaBridge Biosciences' Total Liabilities stood at $162.9 million in 2021, then gained by 0.43% to $163.6 million in 2022, then declined by 24.05% to $124.3 million in 2023, then tumbled by 90.73% to $11.5 million in 2024, then surged by 156.78% to $29.6 million in 2025.
• Business Quant data shows NBP's Total Liabilities at $29.6 million in Q4 2025, $18.5 million in Q3 2025, and $10.0 million in Q2 2025.